Methylene blue mediated photodynamic therapy for resistant plaque psoriasis

Journal of Drugs in Dermatology

Volumn 8, Issue 1, 2009, Pages 42-49

  Salah, Manal ^a   Samy, Nevien ^a   Fadel, Maha ^a  

^a Cairo University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOMER; METHYLENE BLUE; PHOTOSENSITIZING AGENT;

ADULT; ARTICLE; CLEARANCE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISPERSION; DRUG FORMULATION; DRUG RELEASE; FEMALE; FLOW KINETICS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYDROGEL; IN VITRO STUDY; LIGHT EMITTING DIODE; MALE; ORGANOLEPTIC PROPERTY; PH; PHOTODYNAMIC THERAPY; PSORIASIS VULGARIS; SINGLE BLIND PROCEDURE; SKIN BIOPSY; SKIN EXAMINATION; TOPICAL TREATMENT; TREATMENT OUTCOME; VISCOSITY; ADOLESCENT; CLINICAL TRIAL; DRUG RESISTANCE; GEL; MIDDLE AGED; PHOTOCHEMOTHERAPY; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; DRUG RESISTANCE; FEMALE; GELS; HUMANS; MALE; METHYLENE BLUE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PSORIASIS; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 60849105354     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Leonard CL. Overview of psoriasis: Update on current and emerging treatment options. Manag Care. 2003;12(5 Suppl):3-9.
2. Feldman S. Advances in psoriasis treatment. Dermatol Online J. 2000;6(1):4.
3. Rich SJ, Bello-Quintero CE. Advancements in the treatment of psoriasis: Role of biologic agents. J Manag Care Pharm. 2004;10(4):318-325.
4. Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol. 1992;55:145-157.
5. Zeitouni NC, Oseroff AR, Shieh S. Photodynamic therapy for nonmelanoma skin cancers. Current review and update. Mol Immunol. 2003;39:1133-1136. (Pubitemid 36776569)
6. Aghahosseini F, Arbabi-Kalati F, Fashtami LA, et al. Treatment of oral lichen planus with photodynamic therapy mediated methylene blue: A case report. Med Oral Patol Oral Cir Bucal. 2006;11:E126-129.
7. Kupfer A, Aeschilmann C, Wermuth B, Cerny T. Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet. 1994;343:763-764. (Pubitemid 24098694)
8. Canto M, Setrakian S, Petras RE, et al. Methylene blue selectively stains intestinal metaplasia in Barrett's esophagus. Gastrointest Endosc. 2000;44:1-7.
9. American Hospital Formulary Service Drug Information (AHFS) from the American Society of Health-System Pharmacists (ASHP). Available at: http://www.ashp.org/ahfs.
10. Allison RR, Downie GH, Cuenca R, et al. Photosensitizers in clinical PDT. Photodiag Photodynam Ther. 2004;1:27-42. (Pubitemid 40311381)
11. Pena LE. Gel dosage forms: theory, formulation, and processing. In: Osborne DW and Amann AH, eds. Topical Drug Delivery Formulations: Vol. 4. New York, NY: Marcel Dekker, Inc; 1990:381-388
12. Wade A, Weller PJ. Carbomer. In:Handbook of Pharmaceutical Excipients, 2nd ed. The Pharmaceutical press, London, 1994, 71-73.
13. Higuchi T. Mechanism of sustained action medication theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci. 1963:52,1145.
14. SamueivY, Donbrow M, Friedman M. Sustained release of drugs from ethyl cellulose -polyethelen glycol films and kinetics of drug release. J Pharm Sci.1997;68:325-329.
15. Higuchi T. Drug release from wax matrices I analysis of data with first order kinetics and with the diffusion controlled model. J Pharm.Sci. 1968;57(2):274-277.
16. Paulsen E, Korsholm L, Brandrupt F. A double blind, placebo-controlled study of commercial Alo Vera gel in the treatment of slight to moderate psoriasis vulgaris. JEADV. 2005;19:326-331. (Pubitemid 40691710)
17. Thompson M, Feutren G. Psoriasis Area and Severity Index. Novartis Pharma AG. Basel.1997:18.
18. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996;14:485-496. (Pubitemid 26249398)
19. Finaly AY, Coles EC. The effects of severe psoriasis on the quality of life of 360 patients. Br J Dermatol. 1995;132:236-244.
20. Krueger G. Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient membership survey. Arch dermatol. 2001;137:280-284.
21. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-407. (Pubitemid 29418506)
22. Spuls PI, Witkamp L, Bossuyt PM et al. A systematic review of five systemic treatments for severe psoriasis. Br J Dermatol. 1997;137:943-949. (Pubitemid 28011136)
23. Menter A, Baker J, Fonelli W. Psoriasis in practice. Lancet. 1991;338:231-234.
24. Gerber W, Arheilger B, Herman J, Ockenfels H. Ultraviolet B 308-nm Excimer laser treatment of psoriasis: a new phototheraputic approach. Br J Dermatol. 2003;149:1250-1258. (Pubitemid 38058102)
25. Bekassy Z, Astedt B. Carbon dioxide laser vaporization of plaque psoriasis. Br J Dermatol. 1986;114:489-492. (Pubitemid 16101431)
26. Ross AM, Jerome M, Abnoeal D, Hedblad A. Psoriasis response to pulsed dye laser. Lasers in Surg and Med. 1996;19:331-335.
27. Erceg A, Bovenschen HJ, Van de Kerkhof PC, Seyger M. Efficacy of pulsed dye laser in the treatment of localized recalcitrant plaque psoriasis; a comparative study. Br J Dermatol. 2006;155(1):110-114. (Pubitemid 43876402)
28. Bonis B, Kemeny L, Dobozy A et al. 308-nm UVB excimer laser for psoriasis. Lancet 1997;350:1522. (Pubitemid 28036564)
29. Asawanonda P, Anderson R, Chang Y, Taylor C. 308-nm excimer laser for the treatment of psoriasis: a dose-response study. Arch Dermatol. 2000;136:619-624. (Pubitemid 30304943)
30. Mafong E, Friedman P, Kauvar A et al. Treatment of inverse psoriasis with the 308-nm excimer laser. Dermatol Surg 2002;28:530-2. (Pubitemid 34686642)
31. Feldman SR. Remission of psoriasis with excimer laser treatment. J Drugs Dermatol. 2002;1:13-14.
32. RRobinson DJ, Collins P, Stringer MR, et al. Improved response of plaque psoriasis after multiple treatments with topical 5-aminolaevulinic acid photodynamic therapy. Acta Derm Venereol. 1999;79(6):451-455.
33. Fransson J, Ros AM. Clinical and immunohistochemical evaluation of psoriatic plaques treated with topical 5-aminolevulaenic acid photodynamic therapy. Photodermatol Photoimmunol Photomed. 2005;21(6):326-332. (Pubitemid 43009285)
34. Radakovic-Fijan S, Blecha-Thalhammer U, Schleyer V, et al. Topical aminolaevulinic acid based photodynamic therapy as a treatment option for psoriasis? Results of a randomized, observer-blinded study. Br J Dermatol. 2005;152(2):279-283. (Pubitemid 40343598)
35. Schleyer V, Radakovic-Fijan S, Karrer S, et al. Disappointing results and low tolerability of photodynamic therapy with topical 5-aminolaevulinic acid in psoriasis. A randomized, double blind phase I/II study. J Eur Acad Dermatol Venereol. 2006;20(7):823-828. (Pubitemid 44109051)
36. Amy Forman T. Photodynamic therapy: Other Uses. Dermatol Clin. 2007;25:101-109.
37. João Paulo T, Auro Del G, Carla S, et al. Methylene blue in photodynamic therapy: from basic mechanisms to clinical applications. Photodiag Photodynam Thera. 2005;2:175-191.
38. Brown SB, Brown EA, Walker I. The presence and future role of photodynamic therapy in cancer treatment. Lancet Oncol. 2004;5:497-508. (Pubitemid 39069400)
39. Tardivo JP, Del Giglio A, Paaschoal LH, et al. Treatment of melanoma lesions using methylene blue and RL50 light source. Photodiag Photodynam Ther, 2004;1:345-346. (Pubitemid 40460322)
40. Aghahosseini F, Arbabi-Kalati F, Fashtami LA, et al. Methylene blue mediated photodynamic: A possible alternative treatment for oral lichen planus. Lasers Surg Med. 2006; 38(1): 33-38. (Pubitemid 43239595)
41. Bunting JR. A test of singlet oxygen mechanism of cationic dye photosensitization of mitochondrial damage. Photochem Photobiol. 1992;55:81-87.
42. Kessel D, Luo Y. Mitochondrial photodamage and PDT-induced apoptosis. J Photochem Photobiol B. 1998;42(2):89-95. (Pubitemid 28142328)
43. Mellish K, Cox RD, Vernon DI, et al. In vitro photodynamic activity of a series of methylene blue analogues. Photochem Photobiol. 2002;75:392-397.
44. Plaetzer K, Kiesslich T, Oberdanner CB, Krammer B. Apoptosis following photodynamic tumor therapy: induction, mechanisms and detection. Curr Pharma. 2005;11(12):1151-1165. (Pubitemid 40403374)
45. Lemasters JJ. Dying a thousand deaths: redundant pathways from different organelles to apoptosis and necrosis. Gastroentrology. 2005;129:351-360. (Pubitemid 41002067)
46. Gabrielli DS, Belisle E, Severino D, et al. Methylene blue aggregation in liver mouse mitochondria. Photochem Photobiol. 2004;79:227-232.
47. Junqueria HC, Serverino D, Dias LG, et al. Modulation of the methylene blue photochemical properties based on the adsorption at aqueous micelle interfaces. Phys Chem Chem Phys. 2002;4:2320-2328.
48. Severino D, Junqueira HC, Gabrielli DS, et al. Influence of negatively charged interfaces on the ground and excited state properties of methylene blue. Photochem Photobiol. 2003;77:459-468.
49. Jori G, Fabris C. Relative apoptosis and random necrosis in tumor response to photodynamic therapy: effect of the chemical structure of Zn-phtalocyanines. J Photochem Photobiol B. 2000; 43:181-185.
50. Trindade GS, Farias SL, Rumjanek VM, Capella MA. Methylene blue reverts multi drug resistance: sensitivity of multi drug resistant cells to this dye and its photodynamic action. Cancer Lett. 2000;151:161-167. (Pubitemid 30156790)